Lead Product(s) : Rilpivirine Hydrochloride
Therapeutic Area : Oncology
Study Phase : Phase I
Sponsor : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable
Details : SACT-1 (rilpivirine hydrochloride) is an orally administered repurposed small molecule drug for the treatment of neuroblastoma. SACT-1 enhance tumor cell death and suppress MYCN expression.
Brand Name : SACT-1
Molecule Type : Small molecule
Upfront Cash : Not Applicable
June 22, 2023
Lead Product(s) : Rilpivirine Hydrochloride
Therapeutic Area : Oncology
Highest Development Status : Phase I
Sponsor : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable
Lead Product(s) : Dolutegravir Sodium,Rilpivirine Hydrochloride
Therapeutic Area : Infections and Infectious Diseases
Study Phase : Approved
Sponsor : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable
Lupin Receives Tentative Approval from U.S. FDA for Dolutegravir and Rilpivirine Tablets
Details : Dolutegravir Sodium, where dolutegravir is an integrase inhibitor while rilpivirine is a non-nucleoside reverse transcriptase inhibitor (NNRTI) which is used as an oral combination for the treatment of HIV-1 infections in treatment-naive patients.
Brand Name : Dolutegravir/Rilpivirine-Generic
Molecule Type : Small molecule
Upfront Cash : Not Applicable
January 16, 2023
Lead Product(s) : Dolutegravir Sodium,Rilpivirine Hydrochloride
Therapeutic Area : Infections and Infectious Diseases
Highest Development Status : Approved
Sponsor : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable
LOOKING FOR A SUPPLIER?
Reset All
